Drugs / Dazodalibep
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02780388 | May 2016 → May 2018 | rheumatoid arthritis | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT02151110 | May 2014 → May 2016 | — | MedImmune LLC | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT05306353 | Jul 2023 → Jul 2025 | rheumatoid arthritis | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 2 | NCT05201469 | May 2022 → Aug 2026 overdue | lupus nephritis | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 2 | NCT04174677 | Dec 2019 → Dec 2021 | anti-HLA hyperimmunization | Amgen | Withdrawn | No outcome recorded |
| Phase 2 | NCT04129164 | Dec 2019 → Sep 2022 | Sjogren syndrome | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT04163991 | Dec 2019 → Dec 2021 | rheumatoid arthritis | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT04046549 | Oct 2019 → Jul 2022 | transplant rejection | Amgen | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06747949 | Feb 2025 → Dec 2029 expected | Sjogren syndrome | Amgen | Recruiting | No outcome recorded |
| Phase 3 | NCT06245408 | Apr 2024 → Oct 2026 expected | Sjogren syndrome | Amgen | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06104124 | Jan 2024 → Aug 2026 overdue | Sjogren syndrome | Amgen | Active not recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-11-07 | Amgen | AMGEN PRESENTS NEW DATA FROM PHASE 2 TRIAL OF DAZODALIBEP IN SJÖGREN'S SYNDROME AT ACR 2023 amgen.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dazodalibep | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06104124 ↗ |
| Known as | MEDI4920 | “The purpose of the study is to evaluate the efficacy, safety, and tolerability of VIB4920 (formerly MEDI4920) in adult participants with Sjögren's Syndrome (SS).” NCT04129164 ↗ |
| Known as | VIB4920 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04163991 ↗ |
| Action | Inhibit | “Dose-dependent decreases in rheumatoid factor autoantibodies and Vectra DA biomarker score provide additional evidence that VIB4920 effectively blocked the CD40/CD40L pathway.” PMID 31019027 ↗ Apr 20191“CD40 ligand antagonist” CHEMBL4594331 ↗ |
| Modality | Protein / enzyme biologic | “Here, we report the generation and clinical results of a CD40L binding protein, VIB4920, which lacks an Fc domain” PMID 31019027 ↗ Apr 2019 |
| Route | Intravenous | “single IV dose” NCT02151110 ↗ |
| Target | CD40LG | “CD40 ligand antagonist” CHEMBL4594331 ↗ |